Home › Multiple Sclerosis › North Carolina › Raleigh
Multiple Sclerosis clinical trials in Raleigh, NC
3 studies for Multiple Sclerosis are looking for participants at sites in and around Raleigh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
RecruitingPhase 2
- Local Institution - Site 101, Raleigh
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
- TG Therapeutics Investigational Trial Site, Raleigh
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RecruitingPhase 3
- Raleigh Neurology Associates- Site Number : 8400014, Raleigh
About Multiple Sclerosis
Multiple sclerosis (MS) slows down or blocks messages between the brain and body. MS can be mild or severe. Learn about MS symptoms and treatment.
More about Multiple Sclerosis on MedlinePlus
Multiple Sclerosis trials in other cities
- New York City, NY17 studies
- Chicago, IL15 studies
- Boston, MA14 studies
- Washington, DC13 studies
- Cleveland, OH9 studies
- St. Louis, MO8 studies
- Kansas City, KS8 studies
- Birmingham, AL8 studies
- San Francisco, CA8 studies
- Columbus, OH7 studies
- Aurora, CO7 studies
- Baltimore, MD7 studies
Other studies in Raleigh
- Heart Failure7 studies
- Type 2 Diabetes6 studies
- Obesity6 studies
- Coronary Artery Disease6 studies
- Macular Degeneration6 studies
- Stroke5 studies
- Endometrial Cancer5 studies
- Overweight5 studies
- Cardiovascular Disease5 studies
- Atherosclerosis5 studies
- Diabetes4 studies
- Macular Edema4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.